EEDVD-682 is under clinical development by EnGeneIC and currently in Phase II for Head And Neck Cancer. According to GlobalData, Phase II drugs for Head And Neck Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EEDVD-682’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EEDVD-682 overview
EEDVD-682 is under development for treatment of pancreatic ductal carcinoma (PDAC), solid tumors including bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, melanoma, non-small cell lung cancer (NSCLC). The drug candidate is administered intravenously. It consists of EDV nanocells filled with a payload called PNU-159682 (PNU-682). These payload-packaged EDVs are coated with a antibody which targets epidermal growth factor receptor (EGFR). It is based on EnGeneIC s bacterially-derived EDV nanocell platform.
EnGeneIC overview
EnGeneIC is a biopharmaceutical company that develops drugs and other therapeutic molecules. It focuses on developing its proprietary EDV nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV is a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumour cells with minimal toxicity and stimulating the immune system’s innate and adaptive anti-tumour response. It provides preclinical development and clinical trial services. EnGeneIC is headquartered in Sydney, New South Wales, Australia..
For a complete picture of EEDVD-682’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
